Izrael - angleščina - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Izrael - angleščina - Ministry of Health

cts chemical industries ltd, israel - indomethacin - capsules - indomethacin 25 mg - indometacin - indometacin - non steroidal anti-inflammatory indicated for the active stages of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, degenerative joint disease of the hip, acute muscoloskeletal disorders, low back pain.

Evropska unija - angleščina - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 40 mg - capsule, enteric - excipient ingredients: crospovidone; glyceryl monostearate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; purified talc; hyprolose; mannitol; sodium hydroxide; sucrose; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole, quantity: 20 mg - capsule, enteric - excipient ingredients: glyceryl monostearate; mannitol; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; hyprolose; crospovidone; triethyl citrate; purified talc; sodium hydroxide; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate; maize starch - noxicid is indicated for: 1. gastro-oesophageal reflux disease (gord) - treatment of erosive reflux oesophagitis - long-term management of patients with healed oesophagitis to prevent relapse - symptomatic treatment of gastro-oesophageal reflux disease (gord) 2. patients requiring nsaid therapy - short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. - healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy - prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. 3. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion 4. in combination with appropriate antibiotics for: - healing of duodenal ulcer associated with helicobacter pylori - eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: hypromellose; purified talc; hyprolose; macrogol 6000; magnesium stearate; sodium stearylfumarate; glyceryl monostearate; triethyl citrate; microcrystalline cellulose; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; polysorbate 80; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; hypromellose; sodium stearylfumarate; glyceryl monostearate; microcrystalline cellulose; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; povidone; polysorbate 80; macrogol 6000; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg - tablet, enteric coated - excipient ingredients: glyceryl monostearate; crospovidone; polysorbate 80; triethyl citrate; hyprolose; purified talc; magnesium stearate; microcrystalline cellulose; povidone; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; sodium stearylfumarate; macrogol 6000; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: purified talc; hypromellose; crospovidone; polysorbate 80; magnesium stearate; glyceryl monostearate; hyprolose; macrogol 6000; sodium stearylfumarate; triethyl citrate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; microcrystalline cellulose; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.